TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria: (Before the test, all the subjects required for meeting the entry requirements before they join the group)~* female patients;~* The preoperative core needle biopsy or open surgical excision biopsy diagnosis as breast cancer;~* tumor diameter ≤ 3cm;~* No clinical examination of suspicious axillary lymph node-positive;~* diagnosed clinical conditions can be directly surgery as I, II breast cancer patients;~* preoperative clinical or radiologic evidence without distant metastases (M0);~* signed informed consent.~Exclusion criteria: (Before the test, the subjects under any one of items to meet the requirements can not be enrolled)~* Sentinel lymph node biopsy history had received surgery or axillary area;~* multi-center breast cancer or multiple lesions;~* clinical axillary lymph node metastasis have been found;~* mammary area had received neoadjuvant chemotherapy or radiotherapy;~* inflammatory breast cancer;~* pregnancy;~* no personal freedom and independent civil capacity.~Exclusion criteria: (trials, subjects necessary to meet the requirements of any one item, exit the clinical trial research.)~* severe allergic reaction occurs;~* persistent allergic reaction;~* subjects were required to withdraw from a clinical trial;~* researchers consider it not appropriate to continue to participate in the clinical trial investigator.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indocyanine green & methylene blue, (Type: EXPERIMENTAL): Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* PD greater than 3 years~* Stable dose L-dopa but symptoms not adequately controlled and have off time~* Able and willing to complete diary on specific days~Exclusion Criteria:~* Previous use of rotigotine or Neupro~* Atypical Parkinson's syndrome~* Pallidotomy~* Thalamotomy~* Deep brain stimulation~* Fetal tissue transplant~* Dementia~* Psychosis~* Hallucinations~* Epilepsy~* Renal or hepatic dysfunction~* Clinically relevant cardiac dysfunction~* Symptomatic orthostatic hypotension~* Skin sensitivity to adhesives or unresolved contact dermatitis~* History of chronic alcohol or drug abuse~* Pregnant or of child-bearing potential~* Impulse control disorder

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine 2 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 4 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 6 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 8 mg/24 hr (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microparticles in Stored RBC as Potential Mediators of Transfusion Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring coronary artery bypass (CABG) surgery will be enrolled into the study if they: (1) are willing and able to give informed consent and to adhere to study follow up requirements; and (2) do not satisfy any of the exclusion criteria~Exclusion Criteria:~* Patients will be ineligible for the study if they (1) are unable or unwilling to give informed consent; (2) are unable or unwilling to follow the study protocol; (3) are less than 21 years of age; (4) require emergency procedures; (5) require cardiopulmonary bypass (pump) during the operation; (6) require other surgical procedures in addition to coronary artery bypass; (7) have a proven coagulation or platelet disorder; (8) are unwilling to receive blood transfusions; (9) are pregnant; or (10) have cognitive impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transfusion with washed RBC (Type: ACTIVE_COMPARATOR): Subject assigned to this arm will be transfused with washed RBC
- Transfusion with unwashed RBC (Type: ACTIVE_COMPARATOR): Subjects assigned to this arm will be transfused with unwashed RBC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy proven AL amyloidosis.~2. Patients ≥ 18 years of age are eligible.~3. Patient must provide informed consent.~4. All patients must have measurable amyloid organ involvement of a vital organ (eg. heart, liver, kidneys). Localized amyloidosis will also be eligible as long as the amyloid involvement is radiologically measurable.~5. A negative pregnancy test will be required for all women of child bearing potential. Breast feeding is not permitted.~6. Patients who have previously been taking doxycycline will be eligible as long as there is no contraindication to stay on doxycycline 100 mg twice daily (BID) for 1 year in the opinion of the treating physician.~7. Creatinine clearance of \>25 ml/min.~Exclusion Criteria:~1. Patients with severe malabsorption syndrome precluding absorption of oral agents will be excluded.~2. Known intolerance or allergic reactions with doxycycline.~3. Previous chemotherapy for AL amyloidosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetes stable for more than ten days~* no contraindication for steroids~* lumbar stenosis~* articular pain~Exclusion Criteria:~* unstable diabetes~* renal insufficiency

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- methylprednisolone,infiltration (Type: ACTIVE_COMPARATOR): None
- epidural injection (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Gender: Male or female~* Age: \>12 yrs of age~* Clinicla presentation: 1-2 ulcerative lesions, each \< 30 mm in largest diameter, and with a total lesion area \<900 mm2.~* Parasitological confirmation of the lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.~EXCLUSION CRITERIA:~* Previous treatment for leishmaniasis: therapy with Sb, pentamidine, amphotericin B, miltefosine, imidazoles or allopurinol in the last 3 months~* Concomitant diseases by history that would be likely in the PI's opinion to interact, either positively or negatively, with IL Sb treatment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intralesional antimony (Type: EXPERIMENTAL): 3 intralesional injections of antimony at D1, D3 and D7
- Cryotherapy (Type: ACTIVE_COMPARATOR): Liquid nitrogen until freezing at DF1 and D14
- Topical cream (Type: PLACEBO_COMPARATOR): topical treatment 3 times a day during 21 days with an emollient cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Quality of Medical Student Performance at Contextualizing Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fourth-year medical students at University of Illinois at Chicago

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contextualization workshop (Type: EXPERIMENTAL): A four-hour course on contextualization.
- Control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-guided Psychosocial Intervention for Facial Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participant with Facial Palsy:~* Participant is willing and able to give informed consent for participation in the study.~* Aged 18 years or above.~* Current diagnosis of facial palsy, of any severity or aetiology.~* Participants experience one or more psychosocial difficulties related to facial palsy 'all the time' or 'a lot of the time', as assessed by a screening questionnaire~Participant who is a friend, family member or partner of someone with facial palsy:~* Participant is willing and able to give informed consent for participation in the study.~* Aged 18 years or above.~* Is a friend, family member or partner of an adult with facial palsy, of any severity or aetiology.~* Participants experience psychosocial difficulties related to supporting someone with facial palsy, as assessed by participant responding 'all the time' or 'a lot of the time' to one or more questions on a screening questionnaire~Exclusion Criteria:~Participant with Facial Palsy:~* The participant is not in within the target age range (e.g. under the age of 18 years).~* They are not an individual with a current diagnosis of facial palsy.~* They do not speak enough English to understand the questionnaires or ITGs.~* They do not meet eligibility on the screening questionnaire (i.e. they 'never' or 'only occasionally' experience psychosocial difficulties associated with facial palsy (see section 7.2 Screening and Eligibility Assessment).~Participant who is a friend, family member or partner of someone with facial palsy:~* The participant is not in within the target age range (e.g. under the age of 18 years).~* They are not a friend, family member or partner of an adult with a current diagnosis of facial palsy.~* They do not speak enough English to understand the questionnaires or ITG.~* They do not meet eligibility on the screening questionnaire (i.e. they 'never' or 'only occasionally' experience psychosocial difficulties associated with supporting someone with facial palsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Facial Palsy - Trial of ITG (Type: EXPERIMENTAL): In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign informed consent~* Habitually wear multifocal soft/ silicone hydrogel contact lenses~* Require a near spectacle ADD of +0.50 diopters (D) to +2.50D (inclusive)~* Correctable to 20/30 Snellen or 0.2 logarithm minimum angle of resolution (logMAR) or better in each eye at distance~* Willing to wear contact lenses and attend all study visits~Exclusion Criteria:~* Currently wearing DAILIES TOTAL 1® Multifocal or 1-DAY ACUVUE® Moist® Multifocal contact lenses~* Any eye condition that would make contact lens wear unadvisable~* Any use of medication that would make contact lens wear unadvisable~* Prior refractive surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DT1MF, then AMMF (Type: OTHER): Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
- AMMF, then DT1MF (Type: OTHER): Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be adults aged 18 years or older.~* If female, use adequate birth control methods.~* Meet DSM-5 criteria for past-year OUD and have completed buprenorphine induction for OUD.~* Have expressed the intention to receive maintenance (≥6 months) buprenorphine treatment.~* Be willing to receive pharmacist administered buprenorphine maintenance treatment~* Be willing and able to provide written informed consent and HIPAA authorization.~* Be able to read and communicate in English.~* Be able to comply with buprenorphine treatment policies.~Exclusion Criteria:~* Have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study.~* Have known allergy or hypersensitivity to buprenorphine, naloxone, or other components of the buprenorphine/naloxone formulation.~* Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) liver enzymes greater than 5 times the upper limit of normal on screening phlebotomy performed within 60 days prior to the date of the last stabilization visit.~* Have chronic pain requiring ongoing pain management with opioid analgesics.~* Pending legal action or other reasons that might prevent an individual from completing the study (i.e., unable to complete 6 months of pharmacy-based OUD management).~* Pregnant or breastfeeding at the time of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pharmacy opioid use disorder care (Type: OTHER): A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 40 to 44-months-old children, who participated and completed the study V72P6 (NCT00381615; follow-on subjects)~* Healthy 40 to 44-months or 60 to 62-months-old children (naïve subjects)~Exclusion Criteria:~* Previous ascertained or suspected disease caused by N. meningitidis~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component~* Any serious chronic or progressive disease~* Known or suspected impairment/alteration of the immune system~* Receipt of, or intent to immunize with another vaccine, within 30 days prior and after vaccination with the investigational vaccines (within 14 days for licensed flu vaccines)

- Gender: ALL
- Minimum Age: 40 Months
- Maximum Age: 62 Months
- Healthy Volunteers: t

Study Arms:
- 5rMenB (Type: EXPERIMENTAL): Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
- 5rMenB+OMV NZ (Type: EXPERIMENTAL): Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
- 3rMenB (Type: EXPERIMENTAL): Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
- 3rMenB+OMV NZ (Type: EXPERIMENTAL): Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
- Naive_4042 (Type: EXPERIMENTAL): Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
- Naive_6062 (Type: EXPERIMENTAL): Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Infant Formula on Energy Balance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. A healthy, term (≥37 and ≤42 week gestation at birth), singleton infant.~2. Birth weight between 2500 - 4500 grams.~3. At the time of enrollment, infant must be ≤14 days old (Date of birth=day 0).~4. Mother must be 18 years or older.~5. Infant must be consuming a standard cow's milk protein infant formula and have been receiving a standard cow's milk protein infant formula for at least the past 2 days prior to enrollment.~Exclusion Criteria~1. Mother had gestational diabetes during pregnancy~2. Infant has condition requiring infant feedings other than feeding cow milk formula from a bottle.~3. Infant has major congenital malformations (i.e. cleft palate, hemangiomas, extremity malformation).~4. Infant has suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus).~5. Infant has evidence of significant cardiac, respiratory, endocrinologic, hematologic, gastrointestinal, or other systemic diseases. For example, infant must not be receiving insulin or growth hormone.~6. Dyad be the relative (son, daughter, niece, nephew, cousin, aunt, uncle, sibling) of ancillary personnel connected with the study.

- Gender: ALL
- Minimum Age: 1 Week
- Maximum Age: 3 Weeks
- Healthy Volunteers: t

Study Arms:
- Type of Formula: CMF (Type: ACTIVE_COMPARATOR): Infants are randomized to feed standard cow milk formula during first year of life
- Type of Formula: EHF (Type: EXPERIMENTAL): Infants are randomized to feed extensively hydrolyzed infant formula during first year of life

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin.~* Fasting LDL-C \> 70 mg/dL and triglyceride \<=400 mg/dL.~* High or very high risk of incurring a cardiovascular event.~Exclusion Criteria:~* Pregnant or breastfeeding females.~* Cardiovascular or cerebrovascular event of procedures during the past 30 days.~* Congestive heart failure NYHA class IV.~* Poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615; RN316) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete